AstraZeneca provides update on cediranib EU marketing authorisation application

AstraZeneca press release

The decision to withdraw the MAA (Marketing Authorisation Application) was based on outstanding health authority questions that remain at this late stage of the review process. The MAA for cediranib was supported by data from ICON6, a Phase III trial led by the Medical Research Council (MRC) Clinical Trials Unit at UCL. AstraZeneca has not made additional regulatory submissions for cediranib in this indication in any other markets. AstraZeneca is committed to enhancing treatment options for patients with ovarian cancer, including developing chemotherapy-free alternatives to help delay or avoid the use of platinum-based chemotherapies.